List view / Grid view
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
17 October 2011 | By Abbott
ABSORB™ bioresorbable vascular scaffold (BVS) has been recognized as the winner of the Medical Devices category...
4 October 2011 | By Abbott
Abbott's EXCEL is the largest trial to date designed to evaluate optimal treatment strategy in patients with unprotected left main disease...
8 September 2011 | By Abbott
Abbott announced the initiation of ABSORB BTK...
26 August 2011 | By Abbott
Represents significant advance in personalised medicine for patients with non-small-cell lung cancer...
22 August 2011 | By
Abbott has received 510k clearance from the FDA...
16 August 2011 | By Abbott
Two strengths for three-month administration of Lupron Depot-PED ® approved...
10 August 2011 | By Abbott
The U.S. FDA approved the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis...
9 August 2011 | By Abbott
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial...
27 July 2011 | By Abbott
Launch of Abbott’s ARCHITECT® HIV Ag/Ab Combo assay...
15 July 2011 | By Abbott
Abbott plans to develop two new formulations of its HIV medicines...
20 June 2011 | By Abbott
"Lupron Depot is an important treatment option for many patients..."
16 June 2011 | By Abbott
Reata and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes...
14 June 2011 | By Abbott
The U.S. FDA approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat EPI due to cystic fibrosis...
9 June 2011 | By Abbott
After 12 weeks of treatment with levodopa-carbidopa intestinal gel patients reported improvement in motor symptoms...
23 May 2011 | By Abbott
Abbott announced it filed premarket approval applications for a new molecular diagnostic test...
